

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Carlos R. Plata-Salaman et al.
Serial No. :
Filed :
Title : CARABAMATE COMPOUNDS FOR USE IN PREVENTING OR
TREATING ANXIETY DISORDERS

Art Unit :
Examiner :

Honorable Commissioner of Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Dear Sir:

Prior to examination, please amend the above-identified application as follows:

In the Claims:

Please amend claims 20 and 25 as follows:

20. (Amended) The method as in claim 1 wherein anxiety disorders are selected from generalized anxiety disorder, panic disorders, impulse control disorders, phobic disorders, posttraumatic stress disorder, dissociative states (selected from amnesia, somnambulism, dissociative identity disorder or depersonalization), presurgical anxiety states, postsurgical anxiety states or other medical or psychiatric induced anxiety conditions (selected from anxiety resulting from traumatic brain injury, chronic pain disorders or other chronic disease conditions.)
25. The method as in claim 1 wherein the therapeutically effective amount is from about 0.01 mg/Kg/dose to about 100 mg/Kg/dose.

REMARKS/ARGUMENTS

Consideration of the captioned application in view of the foregoing amendments and following remarks is requested.

Claims 1-25 remain in this application. Claims 20 and 25 have been amended.

Early favorable action on the merits is respectfully requested.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page(s) is/are captioned "Version with markings to show changes made".

Applicant respectfully requests that a timely Notice of Allowance be issued in this case.

Respectfully submitted,

By:



Ellen Ciambone Coletti
Reg. No. 34,140

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2359
Dated: February 21, 2002

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

20. (Amended) The method as in claim[s] 1 [or 5] wherein anxiety disorders are selected from generalized anxiety disorder, panic disorders, impulse control disorders, phobic disorders, posttraumatic stress disorder, dissociative states (selected from amnesia, somnambulism, dissociative identity disorder or depersonalization), presurgical anxiety states, postsurgical anxiety states or other medical or psychiatric induced anxiety conditions (selected from anxiety resulting from traumatic brain injury, chronic pain disorders or other chronic disease conditions.)
25. The method as in claim[s] 1 [or 5] wherein the therapeutically effective amount is from about 0.01 mg/Kg/dose to about 100 mg/Kg/dose.